Clinical Trials
298
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (185 trials with phase data)• Click on a phase to view related trials
Intraoperative Paravertebral Block and Postoperative Complications
- Conditions
- Video-assisted Thoracoscopic Surgery (VATS)Lung Cancer (Diagnosis)Pulmonary InfectionsRespiratory Failure Without HypercapniaPleural Effusion Due to Another Disorder (Disorder)AtelectasisBronchospasmPneumothoraxPulmonary Embolism (Diagnosis)Bronchopleural Fistula
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT07211529
- Locations
- 🇨🇳
Tongji Medical College of HUST: Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, Hubei, China
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage
- Conditions
- Intracerebral HaemorrhageMinimally Invasive Treatment
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 768
- Registration Number
- NCT07208097
Prospective Validation Study of a Uterine Fibroid-Related Infertility Prediction Model
- Conditions
- Uterine FibroidsFemale Infertility
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 7084
- Registration Number
- NCT07177534
A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause
- Conditions
- Genitourinary Syndrome of Menopause (GSM)
- Interventions
- Drug: TJAOA103
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 113
- Registration Number
- NCT07160127
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
- Conditions
- Nonalcoholic Fatty Liver DiseaseMetabolic-associated Fatty Liver Disease
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT07149571
- Locations
- 🇨🇳
Tongji hospital, Wuhan, Hubei, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 60
- Next
News
Novel In Vivo CD19 CAR-T Therapy Achieves Complete Remission in Aggressive DLBCL Without Lymphodepletion
A heavily pretreated patient with relapsed/refractory diffuse large B-cell lymphoma achieved complete remission within 28 days following a single dose of Genocury Biotech's novel in vivo CD19 CAR-T therapy.
Sintilimab Plus Bevacizumab Shows Promise in Relapsed Ovarian Clear Cell Carcinoma
A phase II trial (INOVA) found that sintilimab combined with bevacizumab demonstrated activity in patients with relapsed or persistent ovarian clear cell carcinoma.